Ottawa (Reuters) – Canada said on Monday it backed the use of Johnson & Johnson’s Janssen COVID-19 vaccine despite reports of rare blood clots, noting the issue had first been identified in doses made by AstraZeneca PLC.
The federal health ministry said on Twitter it “continues to consider the benefits of vaccination to outweigh these very rare potential risks, and supports the use of the Janssen and AstraZeneca vaccines.”
The first Canadian deliveries of Janssen doses are due this week.
Date:
RecentRelated
For Kuwait’s new emir, Saudi ties are seen as key
Kuwait (Reuters) - Sheikh Meshal al-Ahmad al-Sabah was named...
Pope Francis deplores Israeli killings of civilians at Gaza church
Vatican City (Reuters) - Pope Francis on Sunday again...
Palestinians must find new path from Israeli rule after war, top official says
Ramallah (Reuters) - Immediately after Israel's war in Gaza...
Israel says it struck Hezbollah sites after attacks from Lebanon
Jerusalem/Beirut (Reuters) - Israel said on Sunday it had...